Drug Trial Radar · NCT06764875
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
840
Planned (sponsor's estimate)
Start
Mar 1, 2025
Primary completion
Apr 27, 2029
Study completion Dec 9, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.
Conditions
- HER2-positive Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
Interventions
RilvegostomigDrug
Q3W, intravenous infusion
Trastuzumab deruxtecanDrug
Q3W, intravenous infusion
TrastuzumabDrug
Q3W, intravenous infusion
PembrolizumabDrug
Q3W, intravenous infusion
5-fluorouracilDrug
Q3W, intravenous infusion
CapecitabineDrug
BID, oral administration
CisplatinDrug
Q3W, intravenous infusion
OxaliplatinDrug
Q3W, intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: Up to approximately 6 years
- Overall Survival (OS)Time frame: Up to approximately 6 years
Locations
304 sites in 28 countries. Site status is shown where the registry gives one.
Research Site
Anchorage, Alaska · Recruiting
Research Site
Phoenix, Arizona · Recruiting
Research Site
Duarte, California · Recruiting
Research Site
La Jolla, California · Recruiting
Research Site
Los Alamitos, California · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
Santa Monica, California · Recruiting
Research Site
Solvang, California · Recruiting
Research Site
Upland, California · Recruiting
Research Site
Walnut Creek, California · Recruiting
Research Site
Aurora, Colorado · Recruiting
Research Site
Newark, Delaware · Not yet recruiting
Research Site
Jacksonville, Florida · Recruiting
Research Site
Jacksonville, Florida · Recruiting
Research Site
Orlando, Florida · Recruiting
Research Site
Athens, Georgia · Withdrawn
Research Site
Marietta, Georgia · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Chicago, Illinois · Withdrawn
Research Site
Evanston, Illinois · Recruiting
Research Site
Hinsdale, Illinois · Recruiting
Research Site
Niles, Illinois · Recruiting
Research Site
Dyer, Indiana · Withdrawn
Research Site
Waukee, Iowa · Not yet recruiting
Research Site
Lexington, Kentucky · Not yet recruiting
Research Site
Louisville, Kentucky · Recruiting
Research Site
Silver Spring, Maryland · Recruiting
Research Site
Boston, Massachusetts · Withdrawn
Research Site
Boston, Massachusetts · Withdrawn
Research Site
Worcester, Massachusetts · Withdrawn
Research Site
Detroit, Michigan · Recruiting
Research Site
Grand Rapids, Michigan · Recruiting
Research Site
Burnsville, Minnesota · Withdrawn
Research Site
Kansas City, Missouri · Withdrawn
Research Site
St Louis, Missouri · Recruiting
Research Site
Omaha, Nebraska · Recruiting
Research Site
Reno, Nevada · Recruiting
Research Site
Summit, New Jersey · Recruiting
Research Site
Santa Fe, New Mexico · Recruiting
Showing 40 of 304 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.